Sartorius Aktiengesellschaft

Group H1 2026 sales revenue increased 7.7% on an operational basis in constant currencies; including tariff refund-related effects, sales rose 6.2% in constant currencies and 2.5% reported. Group underlying EBITDA increased 3.9% to EUR 548 million, with margin improving 50 basis points to 30.3%; underlying net profit rose 2% to EUR 172 million and underlying EPS was EUR 2.49 per ordinary share and EUR 2.50 per preference share. Free cash flow increased more than 70% to EUR 208 million, with operating cash flow up almost 26% to EUR 364 million. Full-year guidance was confirmed: group constant-currency sales growth of around 5% to 9%, underlying EBITDA margin slightly above 30%; Bioprocess Solutions growth of 6% to 10% with margin around 32%; Lab Products & Services growth of around 6% with margin slightly below 21%; CapEx ratio around prior-year level; net debt to underlying EBITDA slightly above 3x at year-end. Management also said FX should be about a 2 percentage point headwind to reported revenue growth for the full year.

Michael Grosse framed H1 as evidence that the company’s profitable growth trajectory is intact, saying demand for single-use products, reagents, and productivity-enhancing technology remains strong. He emphasized recovery in equipment, continued strength in consumables, and customer appetite for AI-enabled and digital workflow tools as key strategic tailwinds. His tone was confident but measured, repeatedly separating underlying business performance from tariff-related accounting effects and timing issues.

Florian Funck highlighted three main points: underlying sales are on track, earnings quality improved, and cash generation was very strong. He cited H1 group underlying EBITDA of EUR 548 million, margin of 30.3%, operating cash flow of EUR 364 million, free cash flow of EUR 208 million, net debt of EUR 3.76 billion, and leverage of 3.5x versus 3.55x at year-end 2025. He also said customer compensation for tariff surcharges reduced H1 reported growth by 1.5 percentage points and that the net margin effect from tariffs was negligible, while noting CapEx was EUR 161 million with an 8.9% ratio and that full-year CapEx should be around 12.5% of sales.

Analysts focused on whether H1 trends imply a similar second-half run rate, the impact and duration of delays in advanced modalities, and how tariff refunds affect reported growth. Management said the delayed orders were tied to two late-stage advanced-therapy customers, described the issue as timing rather than cancellation, and said some revenues may shift into 2027. On tariffs, they said the operational view excludes customer compensation and that the H1 tailwind from surcharges will become an H2 headwind if current tariff levels remain; they also said the refund decision was not part of the original guidance because the timing and outcome were uncertain.